Innate immune responses to respiratory syncytial virus infection

Current Topics in Microbiology and Immunology

Volumn 372, Issue , 2013, Pages 139-154

  Mukherjee, Sumanta ^a   Lukacs, Nicholas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GUANINE NUCLEOTIDE BINDING PROTEIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; NOTCH RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN F; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIG I LIKE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; AUTOPHAGY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; EPITHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION;

ADAPTIVE IMMUNITY; CYTOKINES; DENDRITIC CELLS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; MACROPHAGES; RECEPTORS, NOTCH; RECEPTORS, PATTERN RECOGNITION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

EID: 84892682380     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38919-1_7     Document Type: Article

References (59)

1. Aeffner F et al (2011) Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am J Physiol Lung Cell Mol Physiol 301(1):L99-L109
2. Awomoyi AA et al (2007) Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 179(5):3171-3177
3. Becker S, Quay J, Soukup J (1991) Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol 147(12):4307-4312
4. Bermejo-Martin JF et al (2007) Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. Eur Cytokine Netw 18(3):162-167
5. Bonville CA, Rosenberg HF, Domachowske JB (1999) Macrophage inflammatory protein-1alpha and RANTES are present in nasal secretions during ongoing upper respiratory tract infection. Pediatr Allergy Immunol 10(1):39-44
6. Cario E (2008) Innate immune signalling at intestinal mucosal surfaces: a fine line between host protection and destruction. Curr Opin Gastroenterol 24(6):725-732
7. Collins PL, Melero JA (2011) Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162 (1-2):80-99
8. Dallman MJ, Champion B, Lamb JR (2003) Notch signalling in the peripheral immune system. Novartis Found Symp 252:268-276; discussion 276-278
9. Deretic V (2009) Links between autophagy, innate immunity, inflammation and Crohn's disease. Dig Dis 27(3):246-251
10. Douville RN et al (2010) TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus. PLoS ONE 5(8):e12087
11. Ehl S et al (2004) The role of toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus. Eur J Immunol 34(4):1146-1153
12. El Saleeby CM et al (2010) Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr 156(3):409-414
13. El-Sahly HM et al (2000) Spectrum of clinical illness in hospitalized patients with "common cold" virus infections. Clin Infect Dis 31(1):96-100
14. Gagro A et al (2004) Increased toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. Clin Exp Immunol 135(2):267-272
15. Garofalo RP et al (2001) Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 184(4):393-399
16. Graham BS, Johnson TR, Peebles RS (2000) Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 48(3):237-247
17. Groskreutz DJ et al (2006) Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 176(3):1733-1740
18. Haeberle HA et al (2002) Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 186(9):1199-1206
19. Harris J et al (2009) Th1-Th2 polarisation and autophagy in the control of intracellular mycobacteria by macrophages. Vet Immunol Immunopathol 128 (1-3):37-43
20. Hickling TP et al (2000) Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells. Viral Immunol 13(1):125-135
21. Hurwitz JL (2011) Respiratory syncytial virus vaccine development. Expert Rev Vaccines 10(10):1415-1433
22. Hussell T, Openshaw PJ (2000) IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of respiratory syncytial virus but do not enhance the severity of illness in CD8 T cell-immunodeficient conditions. J Immunol 165(12):7109-7115
23. John AE, Berlin AA, Lukacs NW (2003) Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation. Eur J Immunol 33(6):1677-1685
24. Johnson JE et al (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20(1):108-119
25. Johnson TR et al (2009) TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 27(23):3045-3052
26. Johnson TR, McLellan JS, Graham BS (2012) Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J Virol 86(3):1339-1347
27. Jones BG et al (2012) Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30(5):959-968
28. Kurt-Jones EA et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1(5):398-401
29. Li Y et al (2009) Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy 5(4):576-577
30. Lindell DM, Lane TE, Lukacs NW (2008) CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8 (+) T cell efficacy. Eur J Immunol 38(8):2168-2179
31. Lindell DM et al (2011) A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE 6(7):e21823
32. Ling Z, Tran KC, Teng MN (2009) Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 83(8):3734-3742
33. Liu P et al (2007) Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J Virol 81(3):1401-1411
34. Mandelberg A et al (2006) Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis. Clin Exp Immunol 144(1):48-52
35. Mastronarde JG et al (1996) Induction of interleukin (IL)-8 gene expression by respiratory syncytial virus involves activation of nuclear factor (NF)-kappa B and NF-IL-6. J Infect Dis 174(2):262-267
36. McGinnes LW et al (2011) Assembly and immunological properties of Newcastle disease viruslike particles containing the respiratory syncytial virus F and G proteins. J Virol 85(1):366-377
37. Medoff BD et al (2002) IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol 168(10):5278-5286
38. Mellow TE et al (2004) The effect of respiratory synctial virus on chemokine release by differentiated airway epithelium. Exp Lung Res 30(1):43-57
39. Miller AL et al (2003) CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J Immunol 170(6):3348-3356
40. Mukherjee S et al (2009) Regulation of T cell activation by Notch ligand, DLL4, promotes IL-17 production and Rorc activation. J Immunol 182(12):7381-7388
41. Munafo DB, Colombo MI (2001) A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 114 (Pt 20):3619-3629
42. Murawski MR et al (2009) Respiratory syncytial virus activates innate immunity through Tolllike receptor 2. J Virol 83(3):1492-1500
43. Numata M et al (2010) Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci U S A 107(1):320-325
44. Paramore LC, Mahadevia PJ, Piedra PA (2010) Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr Pulmonol 45(6):578-584
45. Rallabhandi P et al (2006) Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 177(1):322-332
46. Rudd BD et al (2005) Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 79(6):3350-3357
47. Rudd BD et al (2006) Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 176(3):1937-1942
48. Sabbah A et al (2009) Activation of innate immune antiviral responses by Nod2. Nat Immunol 10(10):1073-1080
49. Scagnolari C et al (2009) Gene expression of nucleic acid-sensing pattern recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis. Clin Vaccine Immunol 16(6):816-823
50. Schaller MA et al (2007) Notch ligand delta-like 4 regulates disease pathogenesis during respiratory viral infections by modulating Th2 cytokines. J Exp Med 204(12):2925-2934
51. Swanson MS (2006) Autophagy: eating for good health. J Immunol 177(8):4945-4951
52. Tal G et al (2004) Association between common toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189(11):2057-2063
53. Tayyari F et al (2011) Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17(9):1132-1135
54. Tu L et al (2005) Notch signaling is an important regulator of type 2 immunity. J Exp Med 202(8):1037-1042
55. Van De Wetering JK, Van Golde LM, Batenburg JJ (2004) Collectins: players of the innate immune system. Eur J Biochem 271(7):1229-1249
56. Welliver RC (2003) Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 22 (2Suppl):S6-S10; discussion S10-2
57. Xie Z, Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9(10):1102-1109
58. Zhang W et al (2010) Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 84(2):1148-1157
59. Zhou D et al (2005) Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 22(5):571-581